Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) and Biorestorative Therapies (NASDAQ:BRTX – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings and institutional ownership.
Insider & Institutional Ownership
72.8% of Autolus Therapeutics shares are held by institutional investors. Comparatively, 69.4% of Biorestorative Therapies shares are held by institutional investors. 25.7% of Autolus Therapeutics shares are held by insiders. Comparatively, 13.6% of Biorestorative Therapies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Autolus Therapeutics and Biorestorative Therapies”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Autolus Therapeutics | $75.39 million | 5.72 | -$287.53 million | ($1.06) | -1.53 |
| Biorestorative Therapies | $360,000.00 | 5.87 | -$14.24 million | ($21.40) | -0.07 |
Biorestorative Therapies has lower revenue, but higher earnings than Autolus Therapeutics. Autolus Therapeutics is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Autolus Therapeutics and Biorestorative Therapies, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Autolus Therapeutics | 1 | 1 | 3 | 2 | 2.86 |
| Biorestorative Therapies | 1 | 1 | 0 | 0 | 1.50 |
Autolus Therapeutics presently has a consensus target price of $10.00, suggesting a potential upside of 517.28%. Given Autolus Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe Autolus Therapeutics is more favorable than Biorestorative Therapies.
Volatility & Risk
Autolus Therapeutics has a beta of 2.15, indicating that its share price is 115% more volatile than the S&P 500. Comparatively, Biorestorative Therapies has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500.
Profitability
This table compares Autolus Therapeutics and Biorestorative Therapies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Autolus Therapeutics | -238.66% | -178.66% | -49.34% |
| Biorestorative Therapies | -3,088.27% | -508.42% | -230.94% |
Summary
Autolus Therapeutics beats Biorestorative Therapies on 12 of the 14 factors compared between the two stocks.
About Autolus Therapeutics
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.
About Biorestorative Therapies
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
